Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

EGFR Positive Non-small Cell Lung Cancer × pelcitoclax × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroendocrine Tumors 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 EGFR Positive Non-small Cell Lung Cancer 1 Carcinosarcoma 1

Interventions

pelcitoclax 1 osimertinib 1 Injections 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡